From the Editor’s desk....
EASL LiverTree™, Richard Moreau, 218584
JHEP at a glance (May 2018)
EASL LiverTree™, Journal of Hepatology, 218585
EASL Recognition Award Recipient 2018: Prof. Mario Mondelli
EASL LiverTree™, Michael P. Manns, 218588
EASL International Recognition Award Recipient 2018: Prof. Anna Lok
EASL LiverTree™, Marc Ghany, 218589
For whom the interferons toll – TLR7 mediated boosting of innate and adaptive immunity against chronic HBV infection
EASL LiverTree™, Robert Thimme, 218590
Hepatic and cardiac hemodynamics and systemic inflammation in cirrhosis: It takes three to tango
EASL LiverTree™, Minneke J. Coenraad, 218591
New insights into NAFLD and subclinical coronary atherosclerosis
EASL LiverTree™, Lisa VanWagner, 218592
Relaxing access to liver transplantation with living donation: A foolish move or a time to change?
EASL LiverTree™, John G. O'Grady, 218593
Resistance analysis in patients with genotype 1–6 HCV infection treated with sofosbuvir/velpatasvir in the phase III studies
EASL LiverTree™, Evguenia Svarovskaia, 218594
Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis
EASL LiverTree™, Jonas Soderholm, 218595
Anti-HBV response to toll-like receptor 7 agonist GS-9620 is associated with intrahepatic aggregates of T cells and B cells
EASL LiverTree™, Simon Fletcher, 218596
Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism
EASL LiverTree™, Simon Fletcher, 218597
Modelling the elimination of hepatitis C as a public health threat in Iceland: A goal attainable by 2020
EASL LiverTree™, Nick Scott, 218598
Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C
EASL LiverTree™, Manuel Romero Gomez, 218599
Cardiopulmonary hemodynamics and C-reactive protein as prognostic indicators in compensated and decompensated cirrhosis
EASL LiverTree™, Filippo Schepis, 218600
Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations
EASL LiverTree™, Hidewaki Nakagawa, 218601
Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation
EASL LiverTree™, Jörn Schattenberg, 218604
Hsp72 protects against liver injury via attenuation of hepatocellular death, oxidative stress, and JNK signaling
EASL LiverTree™, Pavel Strnad, 218605
Plectin controls biliary tree architecture and stability in cholestasis
EASL LiverTree™, Martin Gregor, 218606
Association between non-alcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study
EASL LiverTree™, Jong-Young Lee, 218607
Controlled attenuation parameter and alcoholic hepatic steatosis: Diagnostic accuracy and role of alcohol detoxification
EASL LiverTree™, Sebastian Mueller, 218608
The molecular functions of hepatocyte nuclear factors – In and beyond the liver
EASL LiverTree™, Adrian Kee Keong Teo, 218609
Development of the liver: Insights into organ and tissue morphogenesis
EASL LiverTree™, Frederic Lemaigre, 218610
Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
EASL LiverTree™, Thomas Jensen, 218611
Should living donor liver transplantation be an option when deceased donation is not?
EASL LiverTree™, Sarah Lieber, 218612
Role of bile acids in the gut-liver axis
EASL LiverTree™, Kai Schneider, 218613
Endothelial JAK2 does not enhance liver lesions in mice with Budd-Chiari syndrome
EASL LiverTree™, Pierre-Emmanuel Rautou, 218614
Visualization of the therapeutic efficacy of a gene correction approach in Wilson’s disease by laser-ablation inductively coupled mass spectrometry
EASL LiverTree™, Ralf Weiskirchen, 218615
Studies of macrophage therapy for cirrhosis – From mice to men
EASL LiverTree™, James A. Thomas, 218616
Reply to: “Studies of macrophage therapy for cirrhosis – From mice to men”
EASL LiverTree™, Hongyan Qin, 218617
Association between beverage consumption and liver fibrosis
EASL LiverTree™, Yisheng Huang, 218620
Reply to: “Association between beverage consumption and liver fibrosis”
EASL LiverTree™, Sarwa Darwish Murad, 218621
“Who killed JR”: Chronic hepatitis C or alcohol use disorders?
EASL LiverTree™, Michaël Schwarzinger, 218622
Reply to: “‘Who killed JR’: Chronic hepatitis C or alcohol use disorders?”
EASL LiverTree™, Maryam Alavi, 218623
Liver resection for BCLC 0-A stage hepatocellular carcinoma: Does the time to surgery not impact the prognosis?
EASL LiverTree™, Wanguang Zhang, 218624
Reply to: “Liver resection for BCLC 0-A stage hepatocellular carcinoma: Does the time to surgery not impact the prognosis”
EASL LiverTree™, Daniel Azoulay, 218625
Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients
EASL LiverTree™, Yun-Fan Liaw, 218626
Reply to: “Stop-and-watch strategy after cessation of nucleos(t)ide analogue therapy in HBeAg-negative patients”
EASL LiverTree™, Thomas Berg, 218627
Coffee consumption and decreased all-cause mortality – What is the true estimate of effect?
EASL LiverTree™, Ehsan Chitsaz, 218628
Reply to: “Coffee consumption and decreased all-cause mortality – What is the true estimate of effect?”
EASL LiverTree™, Maria Patrizia Carrieri, 218629
Sheila Sherlock 100th year anniversary ILC 2018 wrap up session: Closing
EASL LiverTree™, Tom Karlsen, 212777
Complications of cirrhosis and liver transplantation
EASL LiverTree™, Dominique Thabut Damais, 210807
Hepatocellular carcinoma
EASL LiverTree™, Fabio Piscaglia, 210806
Metabolic and cholestatic diseases
EASL LiverTree™, Herbert Tilg, 210805
Sheila Sherlock 100th year anniversary ILC 2018 wrap up session: Chair
EASL LiverTree™, Massimo Pinzani, 210802
Viral hepatitis
EASL LiverTree™, Maria Buti, 210804
Management of AKI in cirrhosis: place of terlipressin, hemofiltration and combined liver and kidney transplantation
EASL LiverTree™, Mitra Nadim, 210792
Liver transplantation in patients with alcohol-related liver disease
EASL LiverTree™, Alexandre Louvet, 210797
Perspectives of personalized medicine in primary liver cancer
EASL LiverTree™, Eric Raymond, 210786
Targeting the gut-liver axis for liver diseases
EASL LiverTree™, Herbert Tilg, 210801
Predicting renal recovery versus non recovery after liver transplantation: the role of kidney biomarkers
EASL LiverTree™, claire FRANCOZ, 210791
Management of alcohol dependence and other co-dependencies
EASL LiverTree™, Lorenzo Leggio, 210796
Viral hepatitis and the community: Addressing the continuum of care: Panel Discussion
EASL LiverTree™, Session Speakers, 212774
From gut to the liver: inflammatory signaling
EASL LiverTree™, Robert Schwabe, 210800
MPP model to expand access to meds
EASL LiverTree™, Ludmila Maistat, 210781
The role of the hepatologist
EASL LiverTree™, Bruno Sangro, 210785
New insights in the mechanisms: interactions between kidney circulatory changes, systemic circulatory changes, systemic inflammation and parenchymal kidney changes
EASL LiverTree™, Paolo Angeli, 210790
Managing obesity and other comorbidities in alcohol-related liver disease
EASL LiverTree™, Arun Sanyal, 210795
Linkage to care
EASL LiverTree™, Philip Bruggmann, 210780
The role of the medical oncologist
EASL LiverTree™, Lorenza Rimassa, 210784
Prevalence and prognostic implications of impaired renal function in cirrhosis: beyond definitions and classifications
EASL LiverTree™, Guadalupe Garcia-Tsao, 210789
Symposium: Multidisciplinary management of alcoholic liver disease: Chair
EASL LiverTree™, Marsha Morgan, 210793
New EASL Clinical Practice Guidelines: Management of alcohol-related liver disease
EASL LiverTree™, Mark R. Thursz, 210794
Pathogenicity of disturbances in the gut-liver axis
EASL LiverTree™, Bernd Schnabl, 210799
EASL-ESMO Symposium: Collaboration between medical oncologists and hepatologists to boost therapeutic advances in liver cancer: Chair
EASL LiverTree™, Prof. Jean-Luc Raoul & Prof. Peter Galle, 214369
Streamlining diagnostics
EASL LiverTree™, Francesco Marinucci, 210779
Access to care in precarious populations (awareness, stigma, self-stigma)
EASL LiverTree™, Nicola Perry, 210778
HCV epidemic EE and Central Asia: current situation
EASL LiverTree™, Olga Golubovskaya, 210775
Elements for an effective response to viral hepatitis in PWID (EU28)
EASL LiverTree™, Thomas Seyler, 210774
The Georgia experience: lessons for viral hepatitis elimination
EASL LiverTree™, John Ward, 210773
Introduction, agenda, setting the goals
EASL LiverTree™, Francesco Negro, 210771
Early assessment of safety and efficacy of tropifexor, a potent non bile-acid FXR agonist, in patients with primary biliary cholangitis: an interim analysis of an ongoing Phase 2 study.
EASL LiverTree™, Christoph Schramm, 210767
JKB-121 in Patients with Nonalcoholic Steatohepatitis: A Phase 2 Double Blind Randomized Placebo Control Study
EASL LiverTree™, Manal Abdelmalek, 210766
The impact of combining Selective Internal Radiation Therapy (SIRT) with sorafenib on overall survival in patients with advanced hepatocellular carcinoma: the SORAMIC trial palliative cohort
EASL LiverTree™, Jens Ricke, 210765
Safety, pharmakokinetics and antiviral activity of novel capsid assembly modulator (CAM) JNJ-56136379 (JNJ-6379) in treatment-naive chronic hepatitis B (CHB) patients without cirrhosis
EASL LiverTree™, Fabien Zoulim, 210764
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated
EASL LiverTree™, Edward Gane, 210763
NGM282, an Engineered Analogue of FGF19, Significantly Improves Markers of Bile Acid Synthesis, Hepatic Injury and Fibrosis in PSC Patients: Results of a Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
EASL LiverTree™, Gideon Hirschfield, 210762
A multicenter, randomized, double-blind, PLB-controlled trial of Galectin-3 inhibitor (GR-MD-02) in patients with NASH cirrhosis and portal hypertension
EASL LiverTree™, Naga Chalasani, 210761
Different bile acids display distinct ability to trigger Nlrp3 inflammasome activation in a cell-dependent manner contributing to cholestatic liver injury and fibrosis
EASL LiverTree™, Maria Eugenia Inzaugarat, 207016
NLRP3 deletion leads to decreased inflammation and prevents fibrosis formation in mice after chronic bile duct ligation.
EASL LiverTree™, Mick Frissen, 207007
Simvastatin-loaded polymeric micelles are a new, safe and effective drug delivery system targeting liver sinusoidal endothelial cells
EASL LiverTree™, Diana Hide, 207048
Fine tuning of SIRT1 expression is essential to protect the liver from cholestasis
EASL LiverTree™, Naiara Beraza, 207021
Ascites NK cells are phenotypically distinct from blood and liver NK cells in patients with liver cirrhosis and become activated by bacterial stimulation in-vitro and during spontaneous bacterial peritonitis
EASL LiverTree™, Philipp Lutz, 207051
Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV / HDV co-infection: 18 month follow-up results from the REP 301-LTF study.
EASL LiverTree™, Andrew Vaillant, 207138
Detection of Hereditary Haemochromatosis in the clinic and community using standard haematological tests: a comparison with iron studies
EASL LiverTree™, John K. Olynyk, 207421
HLA-A2 restricted CD8+ T cell immune hierarchy towards full length Hepatitis E virus (HEV) for T cell-based therapy in chronic HEV. 
EASL LiverTree™, Chai Fen Soon, 207744
The faecal microbiome of patients with primary sclerosing cholangitis has a characteristic signature across different geographic regions
EASL LiverTree™, Timur Liwinski, 207014
Role of Toll-like receptor 4 (TLR4) in regulating severity of hyperammonemia and gene expression of urea cycle enzymes
EASL LiverTree™, Annarein Kerbert, 207043
Basal values and on treatment decline of hepatitis B core-related antigen are predictive of response to interferon therapy in chronic hepatitis D
EASL LiverTree™, Antonella Olivero, 207072
Transient elastography as a screening method for chronic liver disease in apparently healthy population. Results from de ETHON cohort.
EASL LiverTree™, Elba Llop, 207396
Loss of BSEP protects MDR2/ABCB4 KO mice from cholestatic liver injury by altering bile acid profile and signaling
EASL LiverTree™, Claudia Fuchs, 207013
Transcriptome analysis of human and murine cirrhotic livers identifies shared molecular pathways as potential targets to enhance cirrhosis regression
EASL LiverTree™, Erica Lafoz, 207049
A virological response to PEG-IFNa treatment of hepatitis delta is associated with an improved clinical long-term outcome: 10 years follow-up of the HIDIT-1 study
EASL LiverTree™, Anika Wranke, 207133
Non invasive assessment of liver fibrosis by three different Shear Wave Techniques: Head-to-Head Performance
EASL LiverTree™, Sebastiana Atzori, 207416
GENETIC FACTORS OF HEPATIC ENCEPHALOPATHY ON PATIENTS WITH CIRRHOSIS: CANDIDATE GENE STUDY
EASL LiverTree™, Antonio Gil-Gomez, 207063
Patients with genotype 5 hepatitis delta infection have a favourable outcome of disease and better treatment response to pegylated interferon therapy compared to genotype 1 patients 
EASL LiverTree™, Michelle Spaan, 207106
M2 macrophage specfifc gene silencing in the liver using third generations mannose coated, siRNA-loaded nanohydrogel particles
EASL LiverTree™, Leonard Kaps, 207350
EASL-WHO symposium: Meeting the 2030 elimination goals of the WHO viral hepatitis strategy: Panel Discussion
EASL LiverTree™, Session Speakers, 212773
The road ahead – will novel HBV treatments enter clinics soon? Antiviral therapies
EASL LiverTree™, Man-Fung Yuen, 210758
Civil society perspective on the revised 2018 WHO Guidelines and access to treatment
EASL LiverTree™, Giten Khwairakpam, 210749

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.


Save Settings